Jaykay Enterprises Q3 FY26 Revenue Soars 176% to ₹60 Crore, PAT Up 26%
Jaykay Enterprises Ltd. reported strong Q3 FY2026 results with operating revenue at ₹60 crore (up 176% YoY) and PAT at ₹6.8 crore (up 26% YoY). For 9 months FY26, revenue reached ₹178.5 crore (up 156% YoY) and PAT grew to ₹35.8 crore (up 309% YoY). Phase I of the Bengaluru manufacturing project is expected by March 2027.
The substantial increase in revenue and EBITDA, coupled with positive forward-looking statements and significant capital expenditure updates, indicates a high impact on the company's prospects.
The company reported significant year-on-year growth in revenue and EBITDA, along with positive management commentary on future growth and new product development.
Jaykay Enterprises Ltd. (JKE) has announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a significant surge in operating revenue for Q3 FY2026, reaching ₹60 crore, a 176% year-on-year growth. Operating EBITDA also saw a substantial increase of 772% to ₹12.0 crore.
For the nine-month period ended December 31, 2025, operating revenue grew by 156% to ₹178.5 crore, and operating EBITDA rose by 595% to ₹29.9 crore. Profit After Tax before comprehensive income for the third quarter increased by 26% to ₹6.8 crore, while for the nine-month period, it saw a remarkable 309% growth to ₹35.8 crore.
Mr. Abhishek Singhania, Chairman and Managing Director, stated that JKE is aggressively pursuing its goal to become a technology-led leader in Defence and Digital Manufacturing. He highlighted the success of their GenAI-Agentic product, JIVA, in securing new customers.
In other key updates, the 400000 sq ft Precision Manufacturing project at Devanahalli Aerospace Park, Bengaluru, is progressing well, with Phase I expected by March 2027. Expansion at the Cherlapally, Hyderabad plant is complete and trial runs have commenced. The project at Peenya, Bengaluru, is slated for full commissioning by February 2026, and the company has received a Test License from CDSCO to manufacture medical devices (implants), with manufacturing already begun.
What to do with a filing like this
Jaykay Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jaykay Enterprises Limited. Read the original for the full detail.